The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines Renal Cell Carcinoma subcommittee is pleased to invite public comment from August 12 – September 15, 2019, for the draft of the forthcoming "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" manuscript. This is an update from the previous manuscript that published November 15, 2016.
All comments received during the open comment period will be reviewed by the renal cell carcinoma subcommittee and taken into consideration when making final revisions for the manuscript. Comments are advisory only and SITC is not obligated to make any suggested changes based on feedback. SITC will not respond to reviewers. However, all received comments will be published anonymously as an appendix.
PDF ABOUT THE RCC SUBCOMMITTEE
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com